| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.1M | +143.2% | +858.6% |
| SG&A Expense | $6.7M | — | — |
| Operating Income | -$8.8M | — | — |
| Net Income | -$40.4M | — | — |
| EPS (Basic) | -$1.29 | — | — |
| EPS (Diluted) | -$1.29 | — | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $30.2M | — | — |
| Current Assets | $30.5M | — | — |
| Total Assets | $30.5M | — | — |
| Current Liabilities | $605K | +219.7% | +316.8% |
| Total Liabilities | $605K | +219.7% | +316.8% |
| Stockholders' Equity | $29.9M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.5M | — | — |
| Capital Expenditures | $29K | — | — |
| Investing Cash Flow | -$29K | — | — |
| Financing Cash Flow | $30.0M | — | — |
| Free Cash Flow | -$6.5M | — | — |
| — |
| — |